XRTX net incomeFY2025-$2.66M
XRTX net income was -$2.66M for fiscal 2025 (ended Dec 31, 2025), compared with -$3.31M in fiscal 2024.
XORTX Therapeutics Inc. (XRTX) financials
For fiscal 2025 (ended Dec 31, 2025), XORTX Therapeutics Inc. reported -$2.66M of net income.
- Net income, FY2025
- -$2.66M
- EPS, diluted, FY2025
- -$0.56
- Cash
- $864.5K
- Market cap
- $1.5M
FY2021FY2025
FY2022FY2023
XRTX revenue and earnings growth
XRTX EPSFY2025-$0.56
XRTX diluted EPS was -$0.56 for fiscal 2025 (ended Dec 31, 2025).
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Research and development | $574.9K | $183.8K | $2.42M | $6.76M | $677.6K |
| Selling, general and admin | $241.0K | $320.9K | $375.5K | $448.8K | $140.0K |
| Pre-tax income | -$3.26M | -$4.12M | -$6.05M | -$10.29M | -$2.91M |
| Net income | -$2.66M | -$3.31M | -$2.16M | -$7.72M | -$1.58M |
| EPS, basic | -$0.56 | -$1.15 | -$1.09 | -$5.22 | -$1.44 |
| EPS, diluted | -$0.56 | -$1.15 | -$1.09 | -$5.22 | -$1.44 |
| Diluted shares | 4.7M | 2.9M | 2.0M | 1.5M | 1.1M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $864.5K | $2.47M | $3.45M | $10.43M | $14.87M |
| Current assets | $1.26M | $2.68M | $4.07M | $10.90M | $15.91M |
| Total assets | $2.68M | $4.09M | $5.47M | $12.37M | $17.38M |
| Current liabilities | - | - | $294.9K | $1.51M | $552.9K |
| Total liabilities | $599.1K | $758.0K | $825.9K | $5.38M | $4.18M |
| Shareholders' equity | $2.08M | $3.34M | $4.64M | $7.00M | $13.20M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$2.77M | -$3.68M | -$6.58M | -$8.17M | -$4.80M |
| Capital expenditures | - | - | $4.3K | $19.7K | - |
| Free cash flow | - | - | -$6.59M | -$8.19M | - |
| Investing cash flow | -$295.0K | -$38.9K | -$46.4K | -$45.7K | -$31.8K |
| Financing cash flow | $1.43M | $2.78M | -$361.0K | $3.91M | $19.37M |
| Stock-based compensation | $25.2K | $122.5K | $121.0K | $487.9K | $396.4K |
| Depreciation and amortization | $112.1K | $117.3K | $139.7K | $58.1K | $14.3K |
Key ratios
Source: XBRL data XORTX Therapeutics Inc. files with the SEC, latest filing dated Mar 20, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
XRTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| XRTX | - | - | -$2.66M | - | $1.5M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
XRTX FAQ
5 questionsIs XRTX profitable?
No. XORTX Therapeutics Inc. reported a net loss of $2.66M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does XRTX have?
XORTX Therapeutics Inc. reported $864.5K in cash and cash equivalents on its most recent balance sheet in SEC filings.What is XRTX earnings per share?
Diluted earnings per share were -$0.56 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did XRTX last report financial results?
The latest statements here come from XORTX Therapeutics Inc.'s 20-F filed on Mar 20, 2026, covering the period ended Dec 31, 2025.Where does this XRTX financial data come from?
Quantisnow builds these statements from the structured XBRL data XORTX Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.